- Home
- BGLC vs GSUN Comparison
BGLC vs GSUN Comparison
Compare BGLC & GSUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- GSUN
- Stock Information
- Founded
- BGLC 2017
- GSUN 1997
- Country
- BGLC Malaysia
- GSUN China
- Employees
- BGLC N/A
- GSUN N/A
- Industry
- BGLC Medical Specialities
- GSUN Other Consumer Services
- Sector
- BGLC Health Care
- GSUN Real Estate
- Exchange
- BGLC Nasdaq
- GSUN Nasdaq
- Market Cap
- BGLC 5.8M
- GSUN N/A
- IPO Year
- BGLC N/A
- GSUN 2022
- Fundamental
- Price
- BGLC $0.25
- GSUN $2.87
- Analyst Decision
- BGLC
- GSUN
- Analyst Count
- BGLC 0
- GSUN 0
- Target Price
- BGLC N/A
- GSUN N/A
- AVG Volume (30 Days)
- BGLC 1.5M
- GSUN 15.4K
- Earning Date
- BGLC 05-14-2025
- GSUN 04-08-2025
- Dividend Yield
- BGLC N/A
- GSUN N/A
- EPS Growth
- BGLC N/A
- GSUN N/A
- EPS
- BGLC N/A
- GSUN N/A
- Revenue
- BGLC $9,259,858.00
- GSUN $10,159,020.00
- Revenue This Year
- BGLC N/A
- GSUN N/A
- Revenue Next Year
- BGLC N/A
- GSUN N/A
- P/E Ratio
- BGLC N/A
- GSUN N/A
- Revenue Growth
- BGLC N/A
- GSUN 65.04
- 52 Week Low
- BGLC $0.21
- GSUN $2.21
- 52 Week High
- BGLC $1.00
- GSUN $9.93
- Technical
- Relative Strength Index (RSI)
- BGLC 35.57
- GSUN 46.24
- Support Level
- BGLC $0.23
- GSUN $2.80
- Resistance Level
- BGLC $0.29
- GSUN $3.25
- Average True Range (ATR)
- BGLC 0.02
- GSUN 0.21
- MACD
- BGLC -0.01
- GSUN -0.02
- Stochastic Oscillator
- BGLC 20.22
- GSUN 24.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.